Symbiomix caps series A, reports vaginosis data

Symbiomix Therapeutics LLC raised $13 million in the third and final close of its series A round from OrbiMed, Fidelity BioSciences and HBM Partners. The company, which raised a total of $32.5 million in the round, also said a single oral dose of its SYM-1219 met undisclosed primary and secondary endpoints in a 215-patient pivotal Phase II trial to treat bacterial vaginosis.

The granule formulation of secnidazole has Qualifying Infectious Disease Product (QIDP) designation from FDA for the indication. Symbiomix plans to start a Phase III trial this quarter, and to submit an NDA to FDA in mid-2016. ...